XXXII Reunión Anual, Barcelona, 12-13 diciembre 1980

23.- FUXE, K"i AGNATI, L-F.; CORRODI, H.; EVERIT, B.J.; H0KFETT, T.; LOFS-TRON, A. y UNGERSTEDT, U. "Action of doparnine receptor agonists inforebrain and hypothalamus: rotational behaviour, ovulation and dopamineturnover" Advance Ín Neurology. Vol . 9 CALNE, D.B.; CHASE, T.N.;y BARBEU, A. (Ed.) pAg. ?2?-?42. Raven Press. New York (1.975)24.- FUXE, K.; ANDERS0R, K"; SCHAWARCZ, R.; AGNAT, L.F.; PEREZ DE LA MORA,M.;H0KFELT, T.; GOLDSTEIN, M.; FERLAND, L.; P0SSANI, L. y TAPIA, R. "Studieson different types of dopamine nerve terminals in the forebrain and -their possible interaction with hormones and with neurons containingGABA, glutamate and opioid peptides "Advances in Neurology, Vo1 .24 -P0iRIERS, L.J"; SOURKES, T" y BEDARD, P.J. (Ed) pá9. 199-215. RavenPress. New York (1.979 )25.- FUXE, K.; FREDHOLM, B.B.i OGREN, S.0.; AGNATI, L.F. HOKFLET, I.i GUS-TAFSS0N, J.A. "Ergot drugs and central monoaminergic mechanisn a histochemical , biochemical and behavioural analysis". Fed. Proc. 37,2181--2rs1 (1.e78)26.- GARCIA DE YEBENES, J.; CALANDREL Y DIEZ, E. "Improvement in Huntington'sd'isease with lovr dosages of doparninergic agonist "Advances in Neurology.Vol ,23 Págs. 759-763. CHASE, T.N. WEXLEX, N.S. y BARBEU, A. (Ed.)RavenPress. New York (1.979)27.- G0LDSTEIN, M.; LEl^l, J.Y., HATA, F. y LIEBERMAN, A. "Binding interactionsof ergot alkaloids with monoaminergic receptors in the brain" Gerontologie,24(Suppl 1) 76-85 (i.978)28.- GOLDSTEIN, M,; BATTISTA, A.F. y MATSUMOTO, üJ. "Pre and postsynapticeffects of dopanine agonist: antiparkinsonian efficacy and effects ondopamine synthesis" Advances in Parkinsonism. BIRKMAYER, t^1. y H0RNY-KIEWICZ, 0. (Ed.) pág. 236-243. Roche. BASLE (1.976)29"- GOLDSTEIN, 14.; LEI,J, J.Y.; NAKAMURA, S. y BATTISTA, A.F. "Dopamine agonists: antiparkisonism efficacy in experimental animal models and bin:ding to putative amine receptors "Advances in Neurology, Vol .24, POI-RIERS, L"J.; SOURKEZ, T y BEDARD, P.J. (Ed.) pá9.247-252 Raven Press,New York (1.979)30.- G0LDSTEiN, M,; LEl,{, J.K.; NAKAMURA, S.; BATTISTA, A.F.; LIEVERMAN, A.y FUXE, K. "Dopaminerphil ic properties of ergot alkaloids" Fed, Proc.37, 2202-2206 (1.978)31 .- HARDEB0, J.E. y OIJMAN, C. "Barrier mechanisms for neu rotrna sm i tter monoaminesand their precursor at the blood-brain interface" An. Neurol. 8, 1-11 (1.980)32.- KARTZINEL, R.; PERl0tll, M" TEYCHENNE, P. cIELEN, A.C.; GUILLEPIE, M.;SAD0I^ISKY, D.A. y CALNE, D. B" "Bromocriptine and levodova with or withoutcarbi-DOPA in parkinsonism" Lancet, 272-275 (i.976 II)32.-bis KEBABIAN, J.l,.l. y CALNE, D.B, "MultÍp1e receptors for dopamine" Nature277 , 93-96 (i. 979)33.- KEHR, t^l.; CARLSS0N, A. y LINDQUIST, M. "A method for the determinationof 3,4-d'i hydroxyphenyl al ani ne (DOPA) in brain" Naunyn-Sclmiedeberg'sArch. Pharmacol , 274, 273-280 (I.972)